- Home
- Equipment
- netherlands
- cancer drive gene mutations detection
Refine by
Cancer Drive Gene Mutations Detection Equipment Supplied In Netherlands
6 equipment items found
Manufactured by:ScreenPoint Medical based inNijmegen, NETHERLANDS
The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer. “Transpara is now being used by radiologists in clinical practice, but this is only the beginning! We are constantly innovating and we will continue to help doctors to achieve higher breast cancer survival ...
Manufactured by:Lightpoint Medical, Ltd based inWaterside, UNITED KINGDOM
Using next-generation miniaturized sensor technology, the SENSEI probe measures just over 40mm in length, enabling unprecedented intracavity maneuverability and anatomic access for surgical ...
Manufactured by:Self-screen B.V. based inAmsterdam, NETHERLANDS
The QIAsure Methylation Test is intended to be used as a triage test for women with a positive HPV DNA test or for women with ASC-US cytology to identify those women who need to be referred for colposcopy. The QIAsure Methylation Test is a multiplex real-time methylation specific PCR-based (qMSP) assay that detects hyper methylation of 2 disease related marker genes, FAM19A4 and mir124-2, to ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
MDxHealth’s technology platform is called methylation-specific PCR (MSP), which is a proprietary DNA-based technology that functions on standard commercial PCR equipment. MSP is extremely powerful and accurate with the ability to detect a single cancer cell among 10,000 healthy cells in any type of bodily fluid or tissue. MDxHealth has patents and other intellectual property on the MSP ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
ConfirmMDx Addresses Prostate Biopsy Sampling Error and the False-Negative Biopsy Dilemma. “Rule-in” high-risk men who have had a previous negative biopsy result, may be harboring undetected cancer (a false-negative biopsy result), and therefore may benefit from a repeat biopsy and appropriate treatment. “Rule-out” otherwise cancer-free men from undergoing unnecessary ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).1 The test provides binary results that, when combined with the patient’s clinical risk factors, help the ...